A novel paradigm of sensitization of the tumor microenvironment with image-guided ultrasound cavitation and mechanotherapeutics for targeted HCC treatment
通过图像引导超声空化和机械治疗对肿瘤微环境进行敏化的新范例,用于靶向 HCC 治疗
基本信息
- 批准号:10516814
- 负责人:
- 金额:$ 61.01万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-08-15 至 2026-05-31
- 项目状态:未结题
- 来源:
- 关键词:AblationAcademiaAcuteAngiotensin ReceptorAnimalsAntihypertensive AgentsBAY 54-9085Biological AvailabilityBiomedical EngineeringBiophysical ProcessBlood VesselsCancer EtiologyCessation of lifeChemoembolizationClinicalClinical ResearchClinical TrialsDevelopmentDiagnosisDisciplineDiseaseDoseDoxorubicinDrug Delivery SystemsDrug TargetingEffectivenessExcisionFutureGenetic EngineeringGoalsHepatotoxicityIndustryInterventionKnockout MiceLeadLiverLosartanMalignant NeoplasmsMechanicsMediatingMicrobubblesModelingMonitorNatureOncologyOperative Surgical ProceduresOutcomePatientsPharmaceutical PreparationsPharmacotherapyPrimary carcinoma of the liver cellsProceduresPropertyPublic HealthResearchResearch PersonnelResistanceResolutionRiskScientistSystemic TherapyTechniquesTestingTimeToxic effectTransplantationTreatment EfficacyTreatment outcomeWorkadvanced diseasecancer cellcancer typechemotherapeutic agentchemotherapycurative treatmentshuman modelimage guidedimprovedin vivo Modelinnovationinterestliver cancer modelmechanical propertiesmouse modelnovelnovel therapeutic interventionprecision medicinepreclinical efficacypreclinical studypressureresponsesubcutaneoussynergismsystemic toxicitytherapy outcometumortumor microenvironmentultrasounduptake
项目摘要
ABSTRACT
The purpose of this project is to develop a novel image-guided approach for modulating the tumor
microenvironment (TME) of HCC with combined mechanotherapeutic drugs (MechTx) and ultrasound cavitation
treatment (USCTx), and evaluate its therapeutic efficacy. We plan to implement USCTx and the targeting and
monitoring of the combined (with MechTx) treatment on a clinical scanner in order to make it widely available for
future preclinical and clinical studies. Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related
deaths worldwide with an estimated 750,000 new cases per year. Most patients with HCC who are not candidates
for surgical removal or ablation are treated with either transarterial chemoembolization or systemic
chemotherapy. Yet these treatments result in only limited improvements in patient survival at the expense of
considerable toxicities. Our main hypothesis is that the combined USCTx and MechTx will lead to tumor
pressure, stiffness and vascular changes that promote increased local tumor uptake of systemic or transarterial
chemotherapeutics, and will result in better therapy outcomes. While the discovery of new chemotherapeutic
agents and interventional procedures will continue to evolve, our approach to modulate the TME with combined
MechTx and USCTx aims to dramatically improve chemotherapy outcomes with both the existing and future
chemotherapy agents. A strong interdisciplinary team (bioengineers, scientists, clinicians) from academia and
industry will collaborate in the following aims: (Aim 1) Evaluate the ability of MechTx to modulate the tumor
microenvironment and enhance drug delivery; (Aim 2) Evaluate the ability of USCTx to modulate the tumor
microenvironment and enhance drug delivery; (Aim 3) Evaluate the ability of combined MechTx and USCTx to
modulate the tumor microenvironment and enhance drug delivery; and (Aim 4) Demonstrate the preclinical
efficacy of chemotherapeutics when combined with MechTx and USCTx in survival studies using two in vivo
models of HCC. The innovation of the project is in: (a) the use of MechTx as a novel therapeutic strategy to
modulate tumor pressure, microvascular flow, and stiffness of the TME; (b) implementing image-guided USCTx
on a clinical ultrasound scanner leading to translatable precision medicine for HCC; (c) utilizing the synergy of
MechTx and USCTx as a novel and innovative approach for modulating the TME to maximize chemotherapy
outcomes; and (d) combining super resolution and nonlinear Doppler processing to spatially and temporarily
super-resolve the vasculature of tumors undergoing treatments that target the TME. The proposed project will
take advantage of the distinct, yet synergistic mechanisms of MechTx and USCTx as a novel paradigm of
sensitization of the TME to chemotherapeutics, leading to better treatment outcomes and overall survival for
HCC patients initially and patients of other malignancies and diseases in the future.
摘要
该项目的目的是开发一种新的图像引导的方法来调节肿瘤
联合机械治疗药物(MechTx)和超声空化对HCC微环境(TME)的影响
治疗(USCTx),并评估其治疗效果。我们计划实施USCTx和目标定位,
在临床扫描仪上监测(与MechTx)联合治疗,以便广泛用于
未来的临床前和临床研究。肝细胞癌(HCC)是癌症相关的第三大原因。
全世界每年估计有750,000例新病例。大多数非候选人的HCC患者
对于手术切除或消融,采用经动脉化疗栓塞或全身化疗栓塞治疗
化疗然而,这些治疗仅在患者生存方面产生有限的改善,
相当大的毒性。我们的主要假设是USCTx和MechTx的组合将导致肿瘤
压力、僵硬度和血管变化,促进全身或经动脉局部肿瘤摄取增加
化疗药物,并将导致更好的治疗结果。虽然新的化疗药物的发现
药物和介入治疗将继续发展,我们的方法,以调节TME与组合
MechTx和USCTx旨在通过现有和未来的化疗来显著改善化疗结果
化疗药物。一个强大的跨学科团队(生物工程师,科学家,临床医生)来自学术界和
行业将在以下目标方面进行合作:(目标1)评估MechTx调节肿瘤的能力
(2)评价USCTx调节肿瘤的能力
(目的3)评估组合的MechTx和USCTx的能力,
调节肿瘤微环境并增强药物递送;以及(目的4)证明临床前
在使用两种体内试验的生存研究中,化疗药物与MechTx和USCTx联合使用时的疗效
HCC模型该项目的创新之处在于:(a)使用MechTx作为一种新的治疗策略,
调节肿瘤压力、微血管流量和TME的硬度;(B)实施图像引导的USCTx
在临床超声扫描仪上,导致HCC的可平移精确医学;(c)利用以下方面的协同作用:
MechTx和USCTx是一种新型的创新方法,用于调节TME以最大限度地提高化疗效果
(d)结合超分辨率和非线性多普勒处理,
超分辨正在接受靶向TME的治疗的肿瘤的脉管系统。拟议项目将
利用MechTx和USCTx的独特但协同的机制作为一种新的范例,
TME对化疗药物的敏感性,导致更好的治疗结果和总生存期,
最初是肝癌患者,将来是其他恶性肿瘤和疾病患者。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MICHALAKIS AVERKIOU其他文献
MICHALAKIS AVERKIOU的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MICHALAKIS AVERKIOU', 18)}}的其他基金
A novel paradigm of sensitization of the tumor microenvironment with image-guided ultrasound cavitation and mechanotherapeutics for targeted HCC treatment
通过图像引导超声空化和机械治疗对肿瘤微环境进行敏化的新范例,用于靶向 HCC 治疗
- 批准号:
10683239 - 财政年份:2022
- 资助金额:
$ 61.01万 - 项目类别:
相似海外基金
Conference: Rethinking how language background is described in academia and beyond
会议:重新思考学术界及其他领域如何描述语言背景
- 批准号:
2335912 - 财政年份:2024
- 资助金额:
$ 61.01万 - 项目类别:
Standard Grant
ADVANCE Catalyst: Virtual Observatory of Culture for Equity in Academia at the University of Puerto Rico Rio Piedras (VoCEA)
ADVANCE Catalyst:波多黎各 Rio Piedras 大学学术界平等文化虚拟观察站 (VoCEA)
- 批准号:
2214418 - 财政年份:2023
- 资助金额:
$ 61.01万 - 项目类别:
Standard Grant
Comprehensive development strategy of modality-specific "intellectual property" and "cultivation" with an eye on "pharmaceutical affairs" in academia drug discovery
学术界新药研发着眼“药事”的模式“知识产权”与“培育”综合发展策略
- 批准号:
23K02551 - 财政年份:2023
- 资助金额:
$ 61.01万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Accelerating Research Advancement for Investigators Underrepresented in Academia
加速学术界代表性不足的研究人员的研究进展
- 批准号:
10746315 - 财政年份:2023
- 资助金额:
$ 61.01万 - 项目类别:
Planning: HBCU-UP: Strengthening Data Science Research Capacity and Education Programs through Academia-Industry Partnership
规划:HBCU-UP:通过学术界与工业界合作加强数据科学研究能力和教育计划
- 批准号:
2332161 - 财政年份:2023
- 资助金额:
$ 61.01万 - 项目类别:
Standard Grant
From Academia to Business: Development of Novel Therapeutics Against HPV-Associated Cancer
从学术界到商界:针对 HPV 相关癌症的新型疗法的开发
- 批准号:
10813323 - 财政年份:2023
- 资助金额:
$ 61.01万 - 项目类别:
Academics4Rail: Building a community of railway scientific researchers and academia for ERJU and enabling a network of PhDs (academia teaming with industry)
Academys4Rail:为ERJU建立铁路科研人员和学术界社区并建立博士网络(学术界与工业界合作)
- 批准号:
10087488 - 财政年份:2023
- 资助金额:
$ 61.01万 - 项目类别:
EU-Funded
Academics4Rail: Building a Community of Railway Scientific Researchers and Academia for ERJU and Enabling a Network of PhDs (Academia Teaming with Industry)
Academys4Rail:为二院建立铁路科研人员和学术界社区并启用博士网络(学术界与工业界合作)
- 批准号:
10102850 - 财政年份:2023
- 资助金额:
$ 61.01万 - 项目类别:
EU-Funded
Exploring the overall picture of industry-academia-government collaboration: A spectrum of knowledge transfer through formal and informal channels
探索产学官合作的整体图景:通过正式和非正式渠道进行的一系列知识转移
- 批准号:
22K01692 - 财政年份:2022
- 资助金额:
$ 61.01万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Fostering Ethical Neurotechnology Academia-Industry Partnerships: A Stakeholder Engagement and Toolkit Development Project
促进道德神经技术学术界与工业界的伙伴关系:利益相关者参与和工具包开发项目
- 批准号:
10655632 - 财政年份:2022
- 资助金额:
$ 61.01万 - 项目类别: